Herantis Pharma Announces an Oral Presentation and a Poster Presentation related to First-in-Man CDNF Clinical Trial at AD/PD™ Virtual Conference
Herantis Pharma Plc
Company Press Release, 11 March 2021 at 08:00 a.m. EET
Herantis Pharma Plc (“Herantis”), an innovative clinical stage biotech company pioneering new disease modifying and regenerative biologic and gene therapies, announced today that the company will be presenting an oral presentation and a poster presentation summarizing the results from the Phase I-II First-In-Man Clinical Trial of CDNF in Parkinson’s Disease at the 15th International Conference on Alzheimer’s and Parkinson’s Diseases, AD/PD™ 2021 Virtual Conference, March 9-14, 2021.
The oral presentation titled “Phase I-II First-In-Man Clinical Trial of Intraputamenal CDNF In Parkinson’s Disease: Topline Results of the 12-Month Treatment Period” is presented by
company’s co-founder and Chief Science Officer (CSO), Dr. Henri Huttunen as a webcast presentation highlighting the results of the study, please reference the Company’s press release published on August 27, 2020 (link to press release).
The poster presentation is titled “Phase I-II First-In-Man Clinical Trial of Intraputamenal CDNF In Parkinson’s Disease: Exploratory Fluid-Based Biomarker Endpoints of the 12-Month Treatment Period”.
Key Highlights of the presentations:
- Phase I/II topline 12-month data achieved the safety endpoints and exploratory outcome measures produced important insight related to the treatment effect
- Changes indicative of a potential response to CDNF treatment observed in individual patients
- Cerebrospinal Fluid (CSF) biomarker profiling suggesting modulation of proteostasis in response to CDNF treatment
A link to the abstracts can be found here: (Link to ADPD Conference)
After the conclusion of the conference, the abstracts can be found on our website here: (Link to website)
For more information, please contact:
Julie Silber/Gabriela Urquilla
Tel: +46 (0)7 93 486 277/+46 (0)72-396 72 19
Email: ir@herantis.com
Certified Advisor: UB Securities Ltd, Finland: +358 9 25 380 225, Sweden: +358 40 5161400
Company website: www.herantis.com
About CDNF
CDNF is a protein naturally present in humans. It was discovered by Professor Mart Saarma’s laboratory at the University of Helsinki and published in the leading scientific journal, Nature, in 2007. Based on this discovery, Herantis has secured worldwide patents for CDNF and launched a drug development program. The research and development efforts have confirmed that CDNF is a promising neuroprotective and neurorestorative drug candidate, which functions via several mechanisms relevant to neurodegenerative diseases, including Parkinson’s disease. It protects neurons from degeneration, promotes proteostasis and restores the function of already degenerating neurons. This suggests that CDNF has the potential to stop the progression of Parkinson’s disease, which would have a significant therapeutic impact on the lives of patients. If successful, CDNF therapy would enable Parkinson’s patients to improve their quality of life.
CDNF Mode-of-action
CDNF has a multi-modal mechanism by which it improves neuronal survival in Parkinson’s disease and other neurodegenerative diseases. A common feature with many neurodegenerative diseases is the disruption of proteostasis in the brain, resulting in a vicious cycle of pathological accumulation of protein aggregates, neuroinflammation and various forms of cellular stress. Eventually, this results in a gradual loss of neuronal connections and progressive neuronal cell death.
About Herantis Pharma Plc
Herantis Pharma Plc is an innovative clinical stage biotech company with a diverse pipeline of pioneering investigational therapeutics looking to modify the course of debilitating nervous system and lymphatic diseases and break the boundaries of standard therapeutic approaches. Leveraging deep scientific brilliance in protein dysregulation for neurodegenerative diseases, and growth stimulation in lymphatic diseases, Herantis is advancing a rich pipeline of regenerative biological and gene therapies for high impact diseases. These include i. CDNF biological therapy that acts on the proteostatic mechanisms of disease for the treatment of Parkinson’s disease and other neurodegenerative diseases, and ii. Lymfactin® VEGF-C gene therapy for restoring lymphatic structure and function for the treatment of oncology related secondary Lymphedema and other lymphatic based diseases. Herantis is pursuing disease modifying treatments that slow, stop, or even reverse the course of diseases, and bring much needed innovation to these underserved diseases. The shares of Herantis are listed on the Nasdaq First North Growth Market Finland and Nasdaq First North Growth Market Sweden.
For more information, please visit https://www.herantis.com